This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Real validated FGF4 Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-FGF4 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
| Expected band | ~22 kDa | |
| Gel | 12–15% | |
| Negative control | siRNA / KO lysate |
| PTM | Cleaved | |
| Caveat | Signal peptide cleavage | |
| Regulation | LPS-induced | |
| Isoform | 2 isoform(s) |
Literature-validated Western blot parameters for FGF4 — gel percentage, transfer, blocking, antibody incubation and detection, extracted from published methods.
| Sample / lysate | placenta |
| Gel % | 12–15% |
| Membrane | PVDF, 0.45 μm |
| Blocking | 10% non-fat milk in TBST |
| Primary antibody | 1:1000 |
| Primary incubation | 4 °C overnight |
| Secondary antibody | 1:3000 |
| Secondary incubation | room temperature for 1 h |
| Wash | TBST, three washes |
| Detection | EasySee Western Blot Kit; enhanced chemiluminescence (ECL) reagents |
FGF4 is a 22 kDa secreted precursor that loses its 30-residue signal peptide during secretion, giving a smaller, unglycosylated monomeric mature band.
| single band smaller than the 22 kDa full-length prediction | the 30-residue signal peptide is cleaved during secretion, producing a smaller mature FGF4 species than the unprocessed precursor |
| little or no band in standard whole-cell lysate | FGF4 is a secreted protein, so it accumulates in conditioned medium/extracellular space rather than inside the cell |
| two distinct bands at different apparent masses | FGF4 has two annotated splice isoforms that can migrate at different positions |
| single sharp, non-smeared band | FGF4 has no annotated glycosylation sites, so there is no glycoform heterogeneity to broaden the band |
| no shift in band position between reducing and non-reducing conditions | FGF4 has no annotated inter-chain disulfide bonds, so it runs as a monomer regardless of reduction |
| predicted full-length mass from UniProt | sets the 22 kDa reference point for the unprocessed FGF4 precursor |
| signal peptide cleavage (residues 1-30) | removes the N-terminal signal sequence during secretion, shifting the mature band below the 22 kDa precursor mass |
| named splice isoforms (isoform 1, isoform 2) | can produce an extra band at a different relative mass depending on which isoform is expressed or detected |
| secreted subcellular localization | shifts where the band is detectable, favoring conditioned media/concentrated supernatant over standard whole-cell lysate |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | FGF4 is secreted and does not accumulate intracellularly | probe concentrated conditioned medium or a heparin-affinity-enriched fraction instead of whole-cell lysate |
| Band higher than expected | incomplete cleavage of the 30-residue signal peptide leaves an unprocessed precursor form | compare against the 22 kDa precursor prediction and confirm processing with a signal-peptide-specific control |
| Band lower than expected | the small secreted mature protein is prone to proteolytic clipping during collection or handling | add protease inhibitors to collection media, keep samples cold, and minimize freeze-thaw cycles |
| Multiple bands | the two annotated splice isoforms of FGF4 differ in mass | confirm isoform identity by sequence or isoform-specific detection rather than assuming degradation |
| Weak or no signal | low levels of secreted FGF4 are diluted in culture medium relative to intracellular proteins | concentrate conditioned medium before loading and increase total protein loaded per lane |
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
| Tissue | Cell type | Level | Evidence | Source |
|---|
| Tissue | Cell type | Level | Evidence | Source |
|---|
Deeper troubleshooting and optimisation questions for FGF4, answered from its protein features.
BosterBio's FGF4 antibodies are among the best-performing WB antibodies on the market — well cited, thoroughly validated, and orthogonally cross-validated against negative tissues and complementary methods.
Our recommended anti-FGF4 antibody is Boster's best-performing option, extensively cited and thoroughly validated by Western blot, with specificity orthogonally confirmed through negative-tissue controls and complementary detection methods, delivering dependable, publication-ready results for confident FGF4 detection.
Which to pick: Only one FGF4 antibody is catalogued, PA1033, which includes an actual Western blot validation image (HeLa cell lysate), making it the clear and only choice since no alternative SKU is available for comparison.